Company: ZLAB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038548
Chunk: 80

Company: Zai Lab Ltd
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 80
---
31,209 46,527 59,217 Licensing fees— — 19,997 — CROs/CMOs/Investigators expenses19,935 24,305 29,765 44,209 Other costs8,232 6,111 15,054 12,844 Total research and development expenses50,614 61,625 111,343 116,270 

16

Zai Lab Limited Notes to the unaudited condensed consolidated financial statements 

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Clinical programs16,967 21,348 45,059 40,136 Pre-Clinical programs5,069 3,139 8,383 5,188 Unallocated research and development expenses28,578 37,138 57,901 70,946 Total research and development expenses50,614 61,625 111,343 116,270 Three Months Ended June 30,Six Months Ended June 30,2025202420252024Personnel compensation and related costs42,679 48,279 83,322 94,173 Other costs28,359 31,431 51,138 54,731 Total selling, general, and administrative expenses71,038 79,710 134,460 148,904 

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Selling and marketing expenses46,764 53,275 88,703 96,869 General and administrative expenses24,274 26,435 45,757 52,035 Total selling, general, and administrative expenses71,038 79,710 134,460 148,904     

19. Subsequent Events 

On August 6, 2025, the Company entered into a new revolving credit facility with CMB, which replaced its previous RMB250.0 million (approximately $34.4 million) credit facility that expired in July 2025. The Company issued a new maximum-amount irrevocable letter of guarantee to CMB pursuant to which the Company will guarantee working capital loans of up to RMB500.0 million (approximately $69.6 million) from CMB to Zai Lab Shanghai, and Zai Lab Shanghai entered into a Credit Agreement with CMB with respect to the